ANKH and neoplasm: The combination of a single i.t. injection of mANK-101 with systemic PD-1 blockade demonstrated optimal efficacy, with clearance of 100% of injected tumors and 50% of noninjected tumors, leading to a tumor-free survival rate of 50%.